



Suggested Formula	Oseltamivir 12 mg/mL Oral Liquid (Suspension, 75 mL)	FIN	F 001 067v3
-------------------	--	-----	-------------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Oseltamivir (75 mg) Capsules	12	units				
Glycerin, USP	5.0	mL				
Ora-Sweet (oral syrup vehicle)	30.0	mL				
Tutti frutti flavor	1.0	mL				
Ora-Plus (oral suspending vehicle)	q.s. to 75.0	mL				

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Hygroscopic (protect from moisture whenever possible): Glycerin

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error / Testing Considerations: To account for processing error considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.
This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Oseltamivir 12 mg/mL Oral Liquid (Suspension, 75 mL)	FIN	F 001 067v3
-------------------	--	-----	-------------

SUGGESTED PREPARATION (for 75 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Oseltamivir (75 mg) Capsules	12	units			
Glycerin, USP §	5.0	mL			
Ora-Sweet (Oral syrup vehicle)	30.0	mL			
Tutti frutti flavor	1.0	mL			
Ora-Plus (Oral suspending vehicle)	q.s. to 75.0	mL			

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.





Suggested Formula	Oseltamivir 12 mg/mL Oral Liquid (Suspension, 75 mL)	FIN	F 001 067v3
-------------------	--	-----	-------------

Preparatory Instruction

1. **Ingredient quantification (determine the actual quantity of Oseltamivir powder mix to weigh):**

A. Empty and weigh the contents of 14 x Oseltamivir (75 mg) Capsules. Record the total weight here: _____ g

B. Calculate the average weight of powder in each capsule:

Weight of powder from 14 capsules (from Step 1A):	_____ g
DIVIDED BY	
Number of capsules	14
EQUALS	
Average weight of powder from a single Oseltamivir (75 mg) capsule:	_____ g

C. Calculate the weight of powder equivalent to 12 capsules:

Average weight of powder from a single Oseltamivir (75 mg) capsule (from Step 1B):	_____ g
MULTIPLIED BY	
Number of capsules required:	12
EQUALS	
Weight of powder equivalent to 12 capsules:	_____ g

D. Calculate the weight of powder required *plus* processing error adjustments:

Weight of powder equivalent to 12 capsules (from Step 1C):	_____ g
MULTIPLIED BY	
Processing error adjustments (5 to 9%):	1.05 to 1.09
EQUALS	
Weight of powder required <i>plus</i> processing error adjustments:	_____ g

2. **Powder preparation (particle size reduction):**

A. Triturate the contents of the 14 Oseltamivir (75 mg) capsules to form a fine, homogeneous powder.

B. Weigh the quantity of Oseltamivir (75 mg) capsule powder mix required for the batch (refer to Step 1D) and discard the remaining powder.



Suggested Formula	Oseltamivir 12 mg/mL Oral Liquid (Suspension, 75 mL)	FIN	F 001 067v3
3.	<p><u>Powder-liquid preparation:</u></p> <p>A. Levigate the homogeneous fine powder (amount weighed in Step 2B) with the Glycerin.</p> <p><u>End result:</u> Homogeneous paste-like dispersion.</p>		
4.	<p><u>Liquid preparation:</u></p> <p>A. Combine the following ingredients together:</p> <ul style="list-style-type: none">-Ora-Sweet (oral syrup vehicle)-Tutti frutti flavor <p><u>Specifications:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p>		
5.	<p><u>Phase integration:</u></p> <p>A. Incrementally add the homogeneous paste-like dispersion (Step 3A) to the homogeneous liquid-like solution (Step 4A)</p> <p><u>Specifications:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>		
6.	<p><u>Filling to volume:</u></p> <p>A. Add Ora-Plus (oral suspending vehicle) to the mixture (Step 5A) to fill to the required batch size (75.0 mL <i>plus</i> processing error adjustments).</p> <p><u>Specifications:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>		
7.	<p><u>Product transfer:</u></p> <p>Transfer the final product into the specified dispensing container (see “Packaging requirements”).</p> <p><u>Note:</u> Continuously mix the final product during the transfer process into the recommended dispensing containers in order to maintain homogeneity.</p>		



Suggested Formula	Oseltamivir 12 mg/mL Oral Liquid (Suspension, 75 mL)	FIN	F 001 067v3
-------------------	--	-----	-------------

SUGGESTED PRESENTATION

Estimated Beyond-Use Date	14 days, refrigerated.	Packaging Requirements	Suitable prescription bottle with metered dose-measuring device.	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	4	Keep refrigerated. Do not freeze.
	2	Shake well before use.	5	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
	3	Keep out of reach of children.		
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions.			

REFERENCES

1.	Suspensions. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 209.
2.	Oseltamivir Phosphate. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 900.
3.	Oseltamivir (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #6889.
4.	Tamiflu. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties, 2009</i> . 2236.
5.	Oseltamivir Phosphate. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 4th Edition</i> . American Pharmaceutical Association; 2009: 424.
6.	Oseltamivir Systemic. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 2304.
7.	USP <795>. <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 314.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.